ALPINE IMMUNE SCIENCES INC (ALPN) Stock Price, Forecast & Analysis
USA - NASDAQ:ALPN - US02083G1004 - Common Stock
ALPN Key Statistics, Chart & Performance
The current stock price of ALPN is 64.97 USD. In the past month the price increased by 0.65%. In the past year, price increased by 583.9%.
ALPN Latest News, Press Relases and Analysis
ALPN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.94 | 382.94B | ||
| AMGN | AMGEN INC | 14.63 | 172.20B | ||
| GILD | GILEAD SCIENCES INC | 14.97 | 152.10B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.02 | 106.91B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.31 | 68.28B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 852.08 | 56.96B | ||
| ARGX | ARGENX SE - ADR | 62.07 | 51.25B | ||
| INSM | INSMED INC | N/A | 39.50B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.19 | 35.30B | ||
| NTRA | NATERA INC | N/A | 27.44B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.86B | ||
| BIIB | BIOGEN INC | 9.17 | 22.49B |
Related stock screener links
About ALPN
Company Profile
Alpine Immune Sciences, Inc. is a development-stage pharmaceutical company, which engages in the discovery of protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. The company is headquartered in Seattle, Washington and currently employs 126 full-time employees. The company went IPO on 2015-06-17. The firm is focused on discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. The firm's scientific platform uses a directed evolution process to convert native immune system proteins from the immunoglobulin super family (IgSF) into multi-targeted therapeutics capable of modulating the human immune system. The Company’s product candidates include ALPN-101, ALPN-202 and ALPN-303. ALPN-101 is a dual inducible T cell costimulator (ICOS) and cluster of differentiation 28 (CD28) antagonist intended for the treatment of autoimmune and inflammatory diseases. Its oncology program is ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor intended for the treatment of cancer. ALPN-303 is a dual B-cell cytokine antagonist for the treatment of B-cell mediated diseases.
Company Info
ALPINE IMMUNE SCIENCES INC
188 East Blaine St., Suite 200
Seattle WASHINGTON 98102 US
CEO: Mitchell H. Gold
Employees: 126
Phone: 12067884545
ALPINE IMMUNE SCIENCES INC / ALPN FAQ
What does ALPN do?
Alpine Immune Sciences, Inc. is a development-stage pharmaceutical company, which engages in the discovery of protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. The company is headquartered in Seattle, Washington and currently employs 126 full-time employees. The company went IPO on 2015-06-17. The firm is focused on discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. The firm's scientific platform uses a directed evolution process to convert native immune system proteins from the immunoglobulin super family (IgSF) into multi-targeted therapeutics capable of modulating the human immune system. The Company’s product candidates include ALPN-101, ALPN-202 and ALPN-303. ALPN-101 is a dual inducible T cell costimulator (ICOS) and cluster of differentiation 28 (CD28) antagonist intended for the treatment of autoimmune and inflammatory diseases. Its oncology program is ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor intended for the treatment of cancer. ALPN-303 is a dual B-cell cytokine antagonist for the treatment of B-cell mediated diseases.
What is the stock price of ALPINE IMMUNE SCIENCES INC today?
The current stock price of ALPN is 64.97 USD. The price increased by 0.02% in the last trading session.
What is the dividend status of ALPINE IMMUNE SCIENCES INC?
ALPN does not pay a dividend.
What is the ChartMill rating of ALPINE IMMUNE SCIENCES INC stock?
ALPN has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Can you provide the PE ratio for ALPN stock?
ALPINE IMMUNE SCIENCES INC (ALPN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.67).
What is the next earnings date for ALPN stock?
ALPINE IMMUNE SCIENCES INC (ALPN) will report earnings on 2024-08-12, after the market close.
Can you provide the ownership details for ALPN stock?
You can find the ownership structure of ALPINE IMMUNE SCIENCES INC (ALPN) on the Ownership tab.
ALPN Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ALPN. When comparing the yearly performance of all stocks, ALPN is one of the better performing stocks in the market, outperforming 99.78% of all stocks.
ALPN Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ALPN. No worries on liquidiy or solvency for ALPN as it has an excellent financial health rating, but there are worries on the profitability.
ALPN Financial Highlights
Over the last trailing twelve months ALPN reported a non-GAAP Earnings per Share(EPS) of -0.67. The EPS increased by 60.82% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -9.86% | ||
| ROE | -11.07% | ||
| Debt/Equity | 0 |
ALPN Forecast & Estimates
15 analysts have analysed ALPN and the average price target is 62.73 USD. This implies a price decrease of -3.45% is expected in the next year compared to the current price of 64.97.
For the next year, analysts expect an EPS growth of -157.63% and a revenue growth -56.25% for ALPN